1 / 16

Trial profile

Trial profile. Luc F Van Gaal, Lancet 2005;365:1389. Baseline characteristics. Luc F Van Gaal, Lancet 2005;365:1389. A. B. Change from baseline in bodyweight (A) and waist circumference (B). Luc F Van Gaal, Lancet 2005;365:1389.

mura
Download Presentation

Trial profile

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Trial profile Luc F Van Gaal, Lancet 2005;365:1389

  2. Baseline characteristics Luc F Van Gaal, Lancet 2005;365:1389

  3. A B Change from baseline in bodyweight (A) and waist circumference (B) Luc F Van Gaal, Lancet 2005;365:1389

  4. Changes in metabolic and cardiovascular risk factors in ITT population Part I Luc F Van Gaal, Lancet 2005;365:1389

  5. Changes in metabolic and cardiovascular risk factors in ITT population Part II Luc F Van Gaal, Lancet 2005;365:1389

  6. Changes in metabolic and cardiovascular risk factors in ITT population Part III Luc F Van Gaal, Lancet 2005;365:1389

  7. Changes in selected metabolic and cardiovascular risk factors in patients who completed 1 year follow-up Part I Luc F Van Gaal, Lancet 2005;365:1389

  8. Changes in selected metabolic and cardiovascular risk factors in patients who completed 1 year follow-up Part II Luc F Van Gaal, Lancet 2005;365:1389

  9. Changes in selected metabolic and cardiovascular risk factors in patients who completed 1 year follow-up Part III Luc F Van Gaal, Lancet 2005;365:1389

  10. Proportion of patients who lost 5% and 10% of baseline weight at 1 year *p<0.001 vs placebo. †p=0.002 vs placebo. Luc F Van Gaal, Lancet 2005;365:1389

  11. Mean percentage change from baseline in HDL-cholesterol (A) and triglycerides (B) *p<0.001 vs placebo. †p=0.002 vs placebo. Luc F Van Gaal, Lancet 2005;365:1389

  12. Prevalence of the metabolic syndrome in the ITT and completer populations at baseline and after 1 year of treatment Luc F Van Gaal, Lancet 2005;365:1389

  13. Patients reporting adverse events (≥5% in any treatment group) Luc F Van Gaal, Lancet 2005;365:1389

  14. Serious adverse events by system organ classduring the double-blind period of the trial Luc F Van Gaal, Lancet 2005;365:1389

  15. Patients reporting adverse events leading to discontinuation Luc F Van Gaal, Lancet 2005;365:1389

  16. Hypothetical model of role of central and peripheral components of endocannabinoid system in regulation of food intake and peripheral metabolism Luc F Van Gaal, Lancet 2005;365:1389

More Related